← Oncology Approval Tracker

FDA DECISION ·

Kyxata

carboplatin · Avyxa Holdings

FDA approvalNew formulationOvarian cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with advanced ovarian cancer in the initial combination treatment setting, and as a single agent for recurrent ovarian cancer after prior chemotherapy.

LAMPGEN ANALYSIS

Why it matters

A separate carboplatin injection presentation supports established advanced and recurrent ovarian cancer indications.

What research teams should watch

Verify vial strength, renal function and target exposure for dose calculation, and the pharmacy’s specific preparation instructions.

PRIMARY RECORDS

Sources